Brief: Entrada Therapeutics Announces Clinical Candidate For Treatment Of Duchenne Muscular Dystrophy
09/01/2023 13:14
Jan 9 (Reuters) - Entrada Therapeutics Inc TRDA.O :
* ENTRADA THERAPEUTICS ANNOUNCES CLINICAL CANDIDATE,
ENTR-601-45,
FOR THE POTENTIAL TREATMENT OF PEOPLE LIVING WITH DUCHENNE
MUSCULAR DYSTROPHY WHO ARE EXON 45 SKIPPING AMENABLE
* ENTRADA THERAPEUTICS INC- COMPANY PLANS TO SUBMIT AN
INVESTIGATIONAL NEW DRUG (IND) APPLICATION IN SECOND HALF OF
2024
Source text for Eikon: ID:nGNX3qys3H
Further company coverage: TRDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview